PTH and chronic kidney disease: Previous studies have reported that SERMs, bisphosphonates, denosumab, PTH analogs, and sclerostin inhibitors all effectively reduce the risk of fractures, including vertebral, nonvertebral, and hip fractures, in postmenopausal women without CKD (Davis et al., 2020; Author Anonymous, 2021).